Anti-PD1 antibody: Aa new approach to treatment of lymphomas

The Lancet Oncology

Volumn 15, Issue 1, 2014, Pages 7-8

  Bachy, Emmanuel ^a,b,c   Coiffier, Bertrand ^a,b,c  

^a HOSPICES CIVILS DE LYON   (France)

^b UNIVERSITÉ LYON 1   (France)

^c CENTRE HOSPITALIER LYON SUD   (France)

Author keywords

[No Author keywords available]

Indexed keywords

PIDILIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 LIGAND 1 ANTIBODY; PROTEIN ANTIBODY; RITUXIMAB; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG;

DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; DOWN REGULATION; DRUG TARGETING; FOLLICULAR LYMPHOMA; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; LETTER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION;

EID: 84891371901     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(13)70587-4     Document Type: Letter

References (10)

1. Wherry EJ T cell exhaustion. Nat Immunol 2011, 12:492-499.
2. Okazaki T, Maeda A, Nishimura H, Kurosaki T, Honjo T PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine. Proc Natl Acad Sci USA 2001, 98:13866-13871.
3. Quigley M, Pereyra F, Nilsson B, et al. Transcriptional analysis of HIV-specific CD8+ T cells shows that PD-1 inhibits T cell function by upregulating BATF. Nat Med 2010, 16:1147-1151.
4. Berger R, Rotem-Yehudar R, Slama G, et al. Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin Cancer Res 2008, 14:3044-3051.
5. Armand P, Nagler A, Weller EA, et al. Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial. J Clin Oncol 2013, 31:4199-4206.
6. Dave SS, Wright G, Tan B, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 2004, 351:2159-2169.
7. de Jong D, Fest T The microenvironment in follicular lymphoma. Best Pract Res Clin Haematol 2011, 24:135-146.
8. Myklebust JH, Irish JM, Brody J, et al. High PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T cells. Blood 2013, 121:1367-1376.
9. Westin JR, Chu F, Zhang M, et al. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single-group, open-label, phase 2 trial. Lancet Oncol 2013, published online Dec 11. http://dx.doi.org/10.1016/S1470-2045(13)70551-5.
10. Ujjani C, Cheson BD The current status and future impact of targeted therapies in non-Hodgkin lymphoma. Expert Rev Hematol 2013, 6:191-202.